SEOUL, South Korea, Nov. 7, 2024 /PRNewswire/ -- Modern Lion and Hyundai Card have joined NEAR Protocol, a global Layer 1 blockchain platform forming a strategic partnership to advance Web3 integration in the concert culture.
Through its NFT platform KONKRIT, Modern Lion addresses ticket scalping—a priority identified by Hyundai Card—by providing a secure, NFT-based ticketing solution. This partnership will expand Modern Lion's NFT-based ticketing solution on NEAR Protocol, improving security and transparency in ticketing.
Modern Lion has been promoting a healthier concert and show culture through NFT ticketing, successfully preventing scalping at events such as the 'Hyundai Card Curated 92: Jang BEOM-JUNE' concert and the immersive cultural experience 'DaVinci MOTELl' at Itaewon area, Seoul. With NEAR Protocol's speed, security, and scalability, Modern Lion is ready to make significant strides in the global market.
The collaboration will focus on supporting Hyundai Card's event ticketing through NFTs, activating the NFT marketplace, and advancing NFT projects on KONKRIT. Additionally, the partnership will include co-hosting events, joint marketing initiatives, and building brand recognition while strengthening industry networks.
Duhee Lee, CEO of Modern Lion, stated, "This partnership marks a significant step in revolutionizing concert and show culture, blending convenience and security through NFTs and blockchain. By offering NFT tickets and membership services, we will enhance audience experiences and foster transparency in the entertainment industry." He added, "We aim to grow with the NEAR ecosystem and become a globally recognized blockchain company."
Illia Polosukhin, CEO of the NEAR Foundation, highlighted, "Korea is one of the centers for real world adoption of blockchain technology and we are excited that NEAR will partner with Hyundai Card and Modern Lion to provide scalable infrastructure and chain abstracted user experiences."
Modern Lion will also co-host the closing party for the Web3 global conference REDACTED 2024. CEO Duhee Lee will present alongside leading figures from Dragonfly Capital, Pantera Capital, and Edward Snowden, further cementing Modern Lion's role in the global Web3 arena.
Press Contacts:
Luis Shin / Manager
NEAR Korea
Luis@nearkorea.org
About the NEAR Protocol
NEAR is a highly performant, scalable layer one blockchain and ecosystem with tens of millions of monthly active users leading Web3 in consumer app adoption, Chain Abstraction, and User-Owned AI.
For more information, please visit: https://near.org
About NEAR Korea
NEAR Korea manages the business development for NEAR Protocol in Korea and Asia. Its activities include supporting NEAR Protocol projects, fostering developer communities, and driving marketing and branding efforts.
For more information, please visit: https://nearkorea.org/
About Modern Lion
Modern Lion is a blockchain-focused company founded in June 2022. It aims to make blockchain accessible through its NFT marketplace, KONKRIT, which focuses on practical applications like NFT tickets and memberships. By lowering barriers to blockchain adoption, Modern Lion positions itself as an innovative leader in integrating blockchain technology into everyday life.
For more information, please visit: https://modernlion.io/
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Modern Lion and Hyundai Card Partner with NEAR Protocol to Revolutionize Concert Culture with Web3 Integration
National Comprehensive Cancer Network overhauls two major resources to help cancer care providers and other stakeholders stay current on cutting edge research into genetic/familial high-risk assessment.
PLYMOUTH MEETING, Pa., Nov. 7, 2024 /PRNewswire/ -- The National Comprehensive Cancer Network® (NCCN®)—an alliance of leading cancer centers focusing on maintaining evidence-based expert consensus driven guidelines for care—announces the publication of the expanded NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic, and Prostate. This closely follows the recent publication of the expanded NCCN Guidelines® for Genetic/Familial High-Risk Assessment: Colorectal, Endometrial, and Gastric.
Additional cancer types were added to the title and content for both guidelines. These updates account for the growing use of genetic testing in cancer prevention, screening, and treatment.
"These expanded guidelines reflect the recommendations from leading experts on genetic testing based on the latest scientific research across the cancer spectrum, consolidated into two convenient resources," explained Crystal S. Denlinger, MD, Chief Executive Officer, NCCN. "This information is critical for guiding shared decision-making between health care providers and their patients, enhancing screening practices as appropriate, and potentially choosing options for prevention and targeted treatment choices. Genetic testing guidelines enable us to better care for people with cancer and their family members."
The NCCN Guidelines include information on when genetic testing is recommended, and which type of testing may be best. They detail which hereditary conditions and genetic mutations are associated with elevated cancer risk and include follow-up on what to do for people who have them. Those next steps can include instructions for increased screening, or even preventive surgeries or other interventions.
"NCCN has played a major role in the field by creating guideline panels specifically devoted to the genetics of major cancers, and by developing scientifically based guidelines to help providers offer the best genetic-based care to their patients," said Mary B. Daly, MD, PhD, FACP, Fox Chase Cancer Center, Chair of the NCCN Guidelines Panel for Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic, and Prostate. "These guideline panels are continuously active and engaged, constantly responding to new evidence as it becomes available to provide the most up-to-date information to NCCN Guidelines users. These updates include the spectrum of genes associated with genetic syndromes, the range of risk associated with each pathogenic variant, the improvements in screening and prevention strategies, the role of genetic data to inform cancer treatment, and the expansion of the role of genetic counseling as this field moves forward."
"The recently updated NCCN Guidelines for Genetic/Familial High-Risk Assessment: Colorectal, Endometrial, and Gastric takes into account the latest published research and expert opinions from more than 30 experts on caring for individuals with risk for hereditary cancer," said Samir Gupta, MD, UC San Diego Moores Cancer Center, Chair of the NCCN Guidelines Panel for Genetic/Familial High-Risk Assessment: Colorectal, Endometrial, and Gastric. "For the first time, we feature enhanced recommendations for evaluation for endometrial and gastric cancer risk, including: 1) new recommendations for consideration for hereditary cancer screening for all individuals with newly diagnosed endometrial cancer; 2) new recommendations for evaluation and management of CDH1 associated gastric cancer risk; 3) de-implementation of intense colorectal cancer screening for individuals with CHEK2 pathogenic variants; and 4) enhanced recommendations for managing gastric cancer risk in patients with APC pathogenic variants."
The NCCN Guidelines are the recognized standard for clinical recommendations and policy in cancer care and the most frequently updated clinical practice guidelines available in any area of medicine. There are 88 separate subject-specific guidelines, which are maintained by more than 1,900 subject matter experts from across the 33 NCCN Member Institutions. Panels may also include primary care physicians and patient advocates. The NCCN Guidelines are available free-of-charge for non-commercial use at NCCN.org or via the Virtual Library of NCCN Guidelines® App.
About the National Comprehensive Cancer Network
The National Comprehensive Cancer Network® (NCCN®) is a not-for-profit alliance of leading cancer centers devoted to patient care, research, and education. NCCN is dedicated to improving and facilitating quality, effective, equitable, and accessible cancer care so all patients can live better lives. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) provide transparent, evidence-based, expert consensus recommendations for cancer treatment, prevention, and supportive services; they are the recognized standard for clinical direction and policy in cancer management and the most thorough and frequently-updated clinical practice guidelines available in any area of medicine. The NCCN Guidelines for Patients® provide expert cancer treatment information to inform and empower patients and caregivers, through support from the NCCN Foundation®. NCCN also advances continuing education, global initiatives, policy, and research collaboration and publication in oncology. Visit NCCN.org for more information.
Media Contact:
Rachel Darwin
267-622-6624
darwin@nccn.org
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Cancer Genetic Risk Assessment Guidelines Expand to Meet Growing Understanding of Hereditary Risk
